1. Search Result
Search Result
Isoforms Recommended: Galectin-3
Results for "

galectin3

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

3

Natural
Products

7

Recombinant Proteins

8

Antibodies

4

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114409
    GB1107
    Maximum Cited Publications
    19 Publications Verification

    Galectin Cancer
    GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model .
    GB1107
  • HY-19940
    Olitigaltin
    10+ Cited Publications

    TD139; GB0139

    Galectin Inflammation/Immunology
    TD139 is a synthetic galectin-3 inhibitor. TD139 has high affinity for galectin-3 with a Kd of 68 nM, a Kd of 0.22 μM for galectin-1, and a Kd of 38 μM for galectin-7 .
    Olitigaltin
  • HY-126854

    N-Acetyl-D-lactosamine

    Endogenous Metabolite Galectin Cardiovascular Disease
    N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects [3] .
    N-Acetyllactosamine
  • HY-147041
    Selvigaltin
    1 Publications Verification

    GB1211

    Galectin Inflammation/Immunology Cancer
    Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis [3] .
    Selvigaltin
  • HY-101157

    ADC Linker PROTAC Linkers Cancer
    Propargyl-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Propargyl-PEG5-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Propargyl-PEG5-acid
  • HY-114440

    GR-MD-02

    Galectin Apoptosis Cancer
    Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM .
    Belapectin
  • HY-146808

    Galectin Cancer
    Galectin-3 antagonist 1 (compound 15) is a potent and selective Galectin-3 (Gal-3) antagonist with Kd value of 5.3 μM. Meanwhile, Galectin-3 antagonist 1 binds to various Galectin with Kd values of 250 μM (Gal-4N), 18 μM (Gal-4C), 450 μM (Gal-8C), respectively .
    Galectin-3 antagonist 1
  • HY-162561

    Galectin Cancer
    GB1908 is a selective and orally active galectin-1 inhibitor with Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. GB1908 displays >50-fold selectivity over galectin-3. GB1908 can be used for the study of lung cancer .
    GB1908
  • HY-144312

    Galectin Metabolic Disease Cancer
    Thiobis-β-Galactose-propyne is an effective multivalent galectin-3 (Gal-3) inhibitor. Galectin-3 is involved in many metabolism processes related to cancer. Galectin-3-IN-1 is a click chemistry reagent. It contains an alkyne group that can undergo a copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with molecules that have an azide group .
    Thiobis-β-Galactose-propyne
  • HY-170510

    Galectin Cancer
    GB2095 is an orally active and selective galectin-3 inhibitor. GB2095 shows superior selectivity for both human (KD = 0.036 μM) and mouse galectin-3 (KD = 0.35 μM) over other galectins (such as h-Gal-1/4N/4C/8N/8C/9N/9C and m-galectin-1). GB2095 inhibits tumor growth in syngeneic mouse models of breast and melanoma cancers. GB2095 can be used for breast and melanoma cancer research .
    GB2095
  • HY-N16021

    Toll-like Receptor (TLR) Cdc42-binding kinase Galectin Inflammation/Immunology
    4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis [3].
    4A-MPLA ammonium
  • HY-P1592
    G3-C12
    1 Publications Verification

    Galectin Cancer
    G3-C12 is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
    G3-C12
  • HY-173235

    Galectin Cardiovascular Disease Inflammation/Immunology Cancer
    Galectin-3-IN-6 (Compound 12) is a human and murine galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM against human galectin-3, an IC50 of 12.6 nM against mutant murine galectin-3 (V160A), and a Kd of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis .
    Galectin-3-IN-6
  • HY-144313

    Galectin Metabolic Disease Cancer
    Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of galectin-3 (Gal-3; IC50=8.3 μM). Galectin-3 participates in many cancer-related metabolic processes .
    Galectin-3-IN-2
  • HY-P990198

    Galectin Inflammation/Immunology
    Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonal antibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry [3] .
    Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166)
  • HY-163082

    Galectin Cancer
    GB1490 is an orally active galectin inhibitor with Kd values of 0.4 μM and 2.7 μM for galectin-1 and galectin-3, respectively .
    GB1490
  • HY-146809

    Galectin Cancer
    Galectin-3 is a β Galactoside specific carbohydrate recognition protein (lectin) has the ability to promote the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug research.
    Galectin-3 antagonist 2
  • HY-163407

    Galectin Cancer
    Galectin-3-IN-4 (compound 5) is a carboxamide analog. Galectin-3-IN-4 is a potent, selective, and orally bioavailable inhibitor of human and mouse galectin-3, with IC50 values of 21 and 167 nM for hGal-3 and mGal-3, respectively. Galectin-3-IN-4 has IC50 values of 1580 and 2750 nM for hGal-1 and hGal-9, respectively .
    Galectin-3-IN-4
  • HY-179410

    Galectin Others
    Galectin-3-IN-7 is a selective Galectin-3 inhibitor with a Kd of 5.7 nM and shows 390-fold selectivity over Gal-1. Galectin-3-IN-7 can downregulate profibrotic signaling such as ACTA2, COL1A2, and FN1 in TGFβ-stimulated LX2 hepatic stellate cells. Galectin-3-IN-7 can be used for the research of fibrosis .
    Galectin-3-IN-7
  • HY-155191

    Galectin Inflammation/Immunology Cancer
    Galectin-3/galectin-8-IN-1 (Compound 53) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 4.12 μM and 6.04 μM respectively. Galectin-3/galectin-8-IN-1 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-1 can be used for research of cancer and tissue fibrosis .
    Galectin-3/galectin-8-IN-1
  • HY-155192

    Galectin Inflammation/Immunology Cancer
    Galectin-3/galectin-8-IN-2 (Compound 57) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 12.8 μM and 2.06 μM respectively. Galectin-3/galectin-8-IN-2 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-2 can be used for research of cancer and tissue fibrosis .
    Galectin-3/galectin-8-IN-2
  • HY-147041A

    (2S)-GB1211

    Galectin Cancer
    (2S)-Selvigaltin is the S-enantiomer of Selvigaltin (HY-147041). Selvigaltin is an orally active galectin-3 (Gal-3) inhibitor .
    (2S)-Selvigaltin
  • HY-139831

    Galectin Cancer
    Galectin-8-IN-1 is a selective ligand for the galectin-8 N-terminal domain (galectin-8N), with a Kd of 48 μM and 15-fold selectivity over galectin-3 and even better selectivity over the other mammalian galectins.
    Galectin-8-IN-1
  • HY-162789

    Galectin Metabolic Disease Cancer
    Galectin-3-IN-5 (Compound 20) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 9.2 nM against hGal-3 .
    Galectin-3-IN-5
  • HY-170543

    Galectin EGFR Apoptosis Inflammation/Immunology
    Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the KD of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy .
    Dual Galectin-3/EGFR-IN-1
  • HY-163405

    Galectin Cancer
    Galectin-3-IN-3 (Compound 4) is an orally active and selective inhibitor of Gal-3, with IC50 values of 11 nM and 84 nM against mGal-3 and hGal-3 respectively .
    Galectin-3-IN-3
  • HY-P1592A
    G3-C12 TFA
    1 Publications Verification

    Galectin Cancer
    G3-C12 (TFA) is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
    G3-C12 TFA
  • HY-126854R

    N-Acetyl-D-lactosamine (Standard)

    Reference Standards Endogenous Metabolite Galectin Others
    N-Acetyllactosamine (Standard) is the analytical standard of N-Acetyllactosamine. This product is intended for research and analytical applications. N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects[1][2][3][4].
    N-Acetyllactosamine (Standard)
  • HY-130293

    ADC Linker PROTAC Linkers Cancer
    Propargyl-PEG4-CH2CH2-Boc is a non-cleavable ADC linker that can be used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG4-CH2CH2-Boc is a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs . Propargyl-PEG4-CH2CH2-Boc is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Propargyl-PEG4-CH2CH2-Boc
  • HY-163121

    Glycosyltransferase TGF-β Receptor FAK Galectin Collagen Endocrinology Cancer
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease .
    PST3.1a
  • HY-183582

    Galectin Cancer
    GB1841 is an orally active and selective galectin inhibitor with human galectin-1 Kd of 0.027 μM, human galectin-3 Kd of 0.14 μM, mouse galectin-1 Kd of 0.034 μM and mouse galectin-3 Kd of 1.170 μM. GB1841 can be used for the research of lung cancer .
    GB1841
  • HY-P992461

    LAG-3 Cancer
    SHR-1802 is a humanized anti-LAG-3 monoclonal antibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors .
    SHR-1802
  • HY-181783

    Glycosidase STAT Neurological Disease Cancer
    CHI3L1-IN-7 is a selective CHI3L1 inhibitor with a Kd of 7.40 μM and an IC50 of 15.4 μM. CHI3L1-IN-7 blocks CHI3L1's interaction with galectin-3, inhibits STAT3 phosphorylation, reduces the viability of multicellular 3D glioblastoma spheroids. CHI3L1-IN-7 can be used for the research of glioblastoma and CHI3L1-mediated tumor immune regulation .
    CHI3L1-IN-7
  • HY-101157R

    ADC Linker Reference Standards PROTAC Linkers Cancer
    Propargyl-PEG5-acid (Standard) is the analytical standard of Propargyl-PEG5-acid (HY-101157). This product is intended for research and analytical applications. Propargyl-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Propargyl-PEG5-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Propargyl-PEG5-acid (Standard)
  • HY-180937

    Glycosidase STAT Galectin Neurological Disease Cancer
    CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor with a Kd of 19.11 μM for hCHI3L1. CHI3L1-IN-6 blocks CHI3L1-Galectin-3 interaction. CHI3L1-IN-6 reduces STAT3 signaling. CHI3L1-IN-6 exhibits anti-cancer activity against glioblastoma .
    CHI3L1-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: